Aarti Drugs Ltd (AARTIDRUGS) is currently trading at 465.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Aarti Drugs Limited is an integrated pharmaceutical manufacturer focused on active pharmaceutical ingredients (APIs), formulations via Pinnacle Life Science, specialty chemicals and intermediates, operating 14 manufacturing facilities with regulatory approvals including USFDA, EU GMP and UK MHRA across a 100+ country export footprint. FY26 consolidated revenue reached Rs.2,568 crore (+7% YoY) with EBITDA of Rs.312 crore and PAT of Rs.195 crore, reflecting margin resilience despite multi-year pricing pressure; Q1 FY27 showed a sharp recovery with revenue +19% and EBITDA +30%, signalling improving demand or better product mix. Aarti Drugs is a global leader in multiple APIs — largest producer worldwide for several molecules such as Nimesulide, Ketoconazole and Tinidazole — with ~50+ API molecules, an installed capacity of 82,512 MTPA and ~38% export revenue, enabling scale advantages and diversified geographic risk across six continents. Strategically shifting toward regulated markets and an oncology/formulations focus, Aarti Drugs has invested ~Rs.200 crore over 24 months for oncology pipeline development, secured USFDA and UK-MHRA approvals for oncology/OSD lines, and is pursuing 330 regulatory filings across 16 geographies to capture higher realizations and premium pricing.

Over the past 52 weeks, Aarti Drugs Ltd has traded between a low of ₹318.60 and a high of ₹533.60. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Aarti Drugs Ltd has a market capitalization of approximately 4,141.83. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Aarti Drugs Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 21.67 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 4,141.83 Cr, Aarti Drugs Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Aarti Drugs Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Aarti Drugs Ltd is 21.67. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Aarti Drugs reported consolidated revenue of ₹826.24 crore for the quarter ended September 30, 2026. This figure is for Q2 FY27 and includes the performance of the company and its subsidiaries.

He will retire from his roles as Chairman, Managing Director and CEO at the close of business on September 30, 2026.

The GST Department has filed a Special Leave Petition challenging a Bombay High Court order that was favourable to Aarti Drugs and set aside an authority order.

Consolidated revenue was reported at about ₹703 crore, while consolidated PAT was about ₹50 crore for the quarter ended June 30, 2026.